A case for the adoption of pharmacoeconomic guidelines in Japan

Shunya Ikeda, Naoki Ikegami, Adam J. Oliver, Mie Ikeda

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In recent years, more and more Japanese pharmaceutical companies have been submitting pharmacoeconomic data to the government, following the official request that such data may help in setting pharmaceutical prices. The companies have cooperated because, by doing so, they could influence pricing decisions for new products. However, the quality of these data at present is considered to be poor and heavily biased. The introduction of pharmacoeconomic guidelines that outline a set of standardised factors to be included in evaluations are necessary, so that an appropriate comparison of the cost effectiveness of the many new drugs that are introduced onto the Japanese market each year can be made. In addition to supporting the development of standardised guidelines, the Ministry of Health and Welfare should clarify how pharmacoeconomic data are to be used to aid policy decisions and also mandate the publication of pharmacoeconomic data.

Original languageEnglish
Pages (from-to)546-551
Number of pages6
JournalPharmacoEconomics
Volume10
Issue number6
Publication statusPublished - 1996

Fingerprint

Pharmaceutical Economics
Japan
Guidelines
Pharmaceutical Preparations
Decision Support Techniques
Cost-Benefit Analysis
Publications
Costs and Cost Analysis
Health

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Ikeda, S., Ikegami, N., Oliver, A. J., & Ikeda, M. (1996). A case for the adoption of pharmacoeconomic guidelines in Japan. PharmacoEconomics, 10(6), 546-551.

A case for the adoption of pharmacoeconomic guidelines in Japan. / Ikeda, Shunya; Ikegami, Naoki; Oliver, Adam J.; Ikeda, Mie.

In: PharmacoEconomics, Vol. 10, No. 6, 1996, p. 546-551.

Research output: Contribution to journalArticle

Ikeda, S, Ikegami, N, Oliver, AJ & Ikeda, M 1996, 'A case for the adoption of pharmacoeconomic guidelines in Japan', PharmacoEconomics, vol. 10, no. 6, pp. 546-551.
Ikeda S, Ikegami N, Oliver AJ, Ikeda M. A case for the adoption of pharmacoeconomic guidelines in Japan. PharmacoEconomics. 1996;10(6):546-551.
Ikeda, Shunya ; Ikegami, Naoki ; Oliver, Adam J. ; Ikeda, Mie. / A case for the adoption of pharmacoeconomic guidelines in Japan. In: PharmacoEconomics. 1996 ; Vol. 10, No. 6. pp. 546-551.
@article{5952625b5e284ef28fcd7622504b411b,
title = "A case for the adoption of pharmacoeconomic guidelines in Japan",
abstract = "In recent years, more and more Japanese pharmaceutical companies have been submitting pharmacoeconomic data to the government, following the official request that such data may help in setting pharmaceutical prices. The companies have cooperated because, by doing so, they could influence pricing decisions for new products. However, the quality of these data at present is considered to be poor and heavily biased. The introduction of pharmacoeconomic guidelines that outline a set of standardised factors to be included in evaluations are necessary, so that an appropriate comparison of the cost effectiveness of the many new drugs that are introduced onto the Japanese market each year can be made. In addition to supporting the development of standardised guidelines, the Ministry of Health and Welfare should clarify how pharmacoeconomic data are to be used to aid policy decisions and also mandate the publication of pharmacoeconomic data.",
author = "Shunya Ikeda and Naoki Ikegami and Oliver, {Adam J.} and Mie Ikeda",
year = "1996",
language = "English",
volume = "10",
pages = "546--551",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - A case for the adoption of pharmacoeconomic guidelines in Japan

AU - Ikeda, Shunya

AU - Ikegami, Naoki

AU - Oliver, Adam J.

AU - Ikeda, Mie

PY - 1996

Y1 - 1996

N2 - In recent years, more and more Japanese pharmaceutical companies have been submitting pharmacoeconomic data to the government, following the official request that such data may help in setting pharmaceutical prices. The companies have cooperated because, by doing so, they could influence pricing decisions for new products. However, the quality of these data at present is considered to be poor and heavily biased. The introduction of pharmacoeconomic guidelines that outline a set of standardised factors to be included in evaluations are necessary, so that an appropriate comparison of the cost effectiveness of the many new drugs that are introduced onto the Japanese market each year can be made. In addition to supporting the development of standardised guidelines, the Ministry of Health and Welfare should clarify how pharmacoeconomic data are to be used to aid policy decisions and also mandate the publication of pharmacoeconomic data.

AB - In recent years, more and more Japanese pharmaceutical companies have been submitting pharmacoeconomic data to the government, following the official request that such data may help in setting pharmaceutical prices. The companies have cooperated because, by doing so, they could influence pricing decisions for new products. However, the quality of these data at present is considered to be poor and heavily biased. The introduction of pharmacoeconomic guidelines that outline a set of standardised factors to be included in evaluations are necessary, so that an appropriate comparison of the cost effectiveness of the many new drugs that are introduced onto the Japanese market each year can be made. In addition to supporting the development of standardised guidelines, the Ministry of Health and Welfare should clarify how pharmacoeconomic data are to be used to aid policy decisions and also mandate the publication of pharmacoeconomic data.

UR - http://www.scopus.com/inward/record.url?scp=0029821999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029821999&partnerID=8YFLogxK

M3 - Article

C2 - 10164057

AN - SCOPUS:0029821999

VL - 10

SP - 546

EP - 551

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 6

ER -